Avapritinib Value Chain Analysis & Forecast Outlook 2033

Avapritinib by Type (Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%), by Application (Research, Medical), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Avapritinib Market Size | CAGR 13.5 Forecast 2033

Avapritinib Value Chain Analysis & Forecast Outlook 2033

🏭 Chemicals & Materials🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 13.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Avapritinib Market Overview

Avapritinib, marketed as Ayvakit, is a selective tyrosine‑kinase inhibitor targeting PDGFRA and KIT mutations, primarily indicated for gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis. The Avapritinib market size is projected at approximately $260 million in the base year 2025, reflecting its niche yet growing role in precision oncology. This executive‑ready overview highlights the growth outlook, market forecast, and broader industry expansion for the period 2026‑2033, encompassing global demand across therapeutic segments and formulation types.

Loading chart…

The market is expected to expand at a compound annual growth rate (CAGR) of roughly 12% from 2026 to 2033, driven by expanding regulatory approvals, ongoing clinical trials exploring additional oncologic indications, and heightened reimbursement pathways in key jurisdictions. Primary forces shaping the landscape include rapid technology shifts toward companion‑diagnostic integration, evolving regulatory frameworks that streamline orphan‑drug designations, and intensifying competitive intensity as biosimilar pipelines emerge. North America remains the largest revenue contributor, while the Asia‑Pacific region is poised as the fastest‑growing market, propelled by rising cancer incidence, improving healthcare infrastructure, and accelerated adoption of targeted therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	688.50 million
Growth rate	CAGR of 13.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Selleck Chemicals; Cayman Chemical; AbMole; BioVision; Biosynth Carbosynth; Biorbyt; Shimadzu; KareBay Biochem; BOC Sciences; Clearsynth
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Avapritinib market is entering a pivotal phase as recent regulatory approvals and expanding clinical indications drive demand, while pricing pressures and supply considerations shape its trajectory. This dynamics overview highlights the primary forces influencing market size, growth forecast, and strategic positioning for stakeholders.

**Growth Drivers**2 items

Accelerating adoption of precision oncology, especially for PDGFRA‑D842V mutant gastrointestinal stromal tumors (GIST) and systemic mastocytosis, is boosting prescription volumes, directly expanding the Avapritinib market size.

Reimbursement expansions in the United States and Europe, coupled with favorable health‑technology assessments, are reducing payer resistance and enabling broader formulary inclusion, which underpins a robust growth forecast through 2032.

**Restraints**2 items

High acquisition cost relative to alternative TKIs creates budget impact concerns for payers, prompting utilization management programs that can curb volume growth despite clinical efficacy.

Limited real‑world evidence beyond pivotal trials introduces uncertainty around long‑term safety, leading some clinicians to prefer established therapies until larger post‑marketing datasets mature.

**Opportunities**2 items

Ongoing Phase II/III trials investigating combinatorial regimens with immunotherapy agents could unlock new line‑of‑treatment indications, substantially enlarging the addressable patient pool and lifting the Avapritinib market size.

Geographic expansion into emerging markets through local partnerships and tiered pricing models can mitigate pricing barriers, providing a pathway for revenue diversification and supporting the long‑term growth forecast.

**Challenges**2 items

Manufacturing scalability for the complex small‑molecule formulation faces raw‑material bottlenecks, risking supply interruptions that could erode market confidence and affect forecasted growth rates.

Intensifying competition from next‑generation kinase inhibitors and biosimilars may erode market share, compelling the incumbent to invest heavily in differentiated data generation and lifecycle management.

Market Segmentation

Loading chart…

Avapritinib segmentation by type distinguishes the drug’s molecular class from broader therapeutic modalities. The primary type is a small‑molecule oral kinase inhibitor, designed to bind the ATP‑binding pocket of mutant KIT and PDGFRA proteins. This classification contributes the majority of market revenue because it aligns with the drug’s FDA‑approved indication and enables outpatient administration, reducing infusion‑center costs. Pricing for the oral formulation averages $12,000 per treatment cycle in the United States, and reimbursement pathways through Medicare Part D further solidify its revenue contribution. A secondary type emerging in the market is investigational combination therapy, where avapritinib is co‑administered with agents such as immunotherapy or other targeted inhibitors in clinical trials. Although still experimental, this sub‑type adds incremental volume by expanding the patient pool beyond the approved indications and attracting research funding. By separating these types, analysts can isolate the stable, reimbursable sales stream from the volatile, trial‑driven revenue, thereby refining the overall Avapritinib market size estimate.

Avapritinib segmentation by application isolates its clinical use into two principal therapeutic areas: gastrointestinal stromal tumor (GIST) harboring PDGFRA D842V mutations, and advanced systemic mastocytosis (SM) including aggressive and mast cell leukemia subtypes. The GIST application accounts for roughly 70 % of total sales, driven by a prevalence of 1.5 cases per 100,000 population and the absence of effective alternatives for the D842V mutation. Reimbursement rates are high, and the drug’s oral dosing schedule supports long‑term adherence, reinforcing its dominant share. The SM application contributes the remaining 30 %, reflecting a smaller patient base but a high unmet medical need; avapritinib is the only FDA‑approved agent for advanced SM, leading to premium pricing and specialist‑center uptake. Ongoing Phase III trials evaluating avapritinib in earlier‑line GIST settings could expand the addressable population, potentially shifting the segment proportion upward over the next five years. Together, these application segments define the market taxonomy for avapritinib, with the GIST segment providing volume stability and the SM segment delivering higher per‑patient revenue, both essential for the aggregate market size.

Avapritinib Segmentation Breakdown7 items

Type

Min Purity Less Than 98%

Min Purity 98%-99%

Min Purity More Than 99%

Application

Research

Medical

Regional Insights

Loading chart…

The Avapritinib market continues to expand globally, with North America remaining the largest contributor and Asia Pacific emerging as the fastest‑growing region. Stakeholders monitor the regional forecast to align investment and launch strategies.

North America benefits from mature oncology ecosystems, strong reimbursement frameworks, and accelerated FDA pathways that expedite Avapritinib adoption across major health systems. Ongoing biotech venture capital inflows further reinforce pipeline development.

Europe’s growth is driven by centralized health‑technology assessments, pan‑EU pricing negotiations, and robust clinical‑trial networks that support real‑world evidence generation for the drug.

Asia Pacific sees rapid Avapritinib market growth thanks to expanding private oncology clinics, government‑backed rare‑disease initiatives, and rising middle‑class demand for targeted therapies in China, Japan, and South Korea.

Latin America’s uptake is propelled by improving insurance coverage, Brazil’s regulatory harmonization, and increasing participation in multinational trials that raise awareness of GIST and PDGFRA mutations.

Middle East & Africa are gaining traction via government oncology funding, UAE’s advanced hospital infrastructure, and growing partnerships with global pharma that accelerate market entry and physician education.

Competitive Landscape

The Avapritinib competitive landscape is moderately consolidated, with a handful of multinational suppliers accounting for a sizable portion of volume while a broader set of regional distributors fills niche indications. Global players dominate pricing negotiations and regulatory pathways, whereas local firms compete on faster market entry and tailored logistics. Key levers shaping competition include pricing elasticity, breadth of distribution networks, speed of regulatory approvals, and the ability to introduce incremental product innovations such as novel salt forms or formulation improvements. Certification status (e.g., GMP, ISO) remains a decisive factor for hospital procurement committees, and supply‑chain resilience continues to differentiate firms that can guarantee uninterrupted availability.

Across the segment, firms pursue M&A to acquire specialized synthesis capabilities, form OEM partnerships to broaden channel reach, and launch next‑generation analogues to extend patent life. Geographic expansion into emerging markets is paired with localized R&D centers that adapt the molecule for region‑specific dosing regimens. Differentiation often hinges on proprietary chemistry platforms, cost‑effective manufacturing footprints, and value‑added services such as analytical support or custom packaging. However, escalating compliance costs and margin pressure from price‑controlled health systems impose a persistent challenge, compelling players to balance cost structures against the need for continuous innovation.

Selleck Chemicals regional expansion

Cayman Chemical vertical integration

AbMole premium pricing

BioVision OEM tie‑ups

Biosynth Carbosynth local manufacturing

Biorbyt innovation pipeline

Key Avapritinib Companies10 items

Selleck Chemicals

Cayman Chemical

AbMole

BioVision

Biosynth Carbosynth

Biorbyt

Shimadzu

KareBay Biochem

BOC Sciences

Clearsynth

Market Ecosystem

The Avapritinib ecosystem spans a defined value chain that begins with upstream raw‑material sourcing, proceeds through midstream manufacturing and formulation activities, and culminates in downstream distribution and clinical delivery. Upstream participants such as API and excipient suppliers provide the chemical building blocks that enable drug substance synthesis. Midstream actors—including contract manufacturers, formulation technology firms, and contract development organizations—transform these inputs into a stable, patient‑ready product under strict Good Manufacturing Practice controls. The chain also integrates financing partners that provide credit facilities for high‑cost manufacturing equipment, further linking upstream investment to downstream availability. Downstream channels consist of temperature‑controlled logistics providers, specialty pharmacy networks, and clinical service organizations that ensure the medication reaches oncologists, hospitals, and ultimately patients while maintaining compliance with regulatory mandates. Value is captured at each stage through service fees, licensing arrangements, and reimbursement mechanisms, creating interdependencies that shape market dynamics.

API suppliers — provide active pharmaceutical ingredients and excipients required for Avapritinib formulation.

Contract manufacturers — execute scale‑up, fill‑finish, and packaging under GMP standards.

Formulation technology providers — supply proprietary delivery platforms and stability solutions for the drug product.

Logistics & distribution partners — manage temperature‑controlled transport from manufacturing sites to market.

Specialty pharmacy networks — handle patient‑level dispensing, insurance coordination, and adherence programs.

Clinical service providers — deliver trial support, pharmacovigilance, and patient education services.

Regulatory agencies — set approval criteria, labeling requirements, and post‑marketing surveillance obligations.

Control of the Avapritinib ecosystem resides primarily with regulators, specialty pharmacy networks, and reimbursement bodies, as their decisions dictate market entry and patient access. Dependency risks emerge from limited API sourcing options, stringent GMP compliance, and the need for continual regulatory approvals for label expansions. High switching costs for manufacturers—linked to validated production lines and cold‑chain logistics—reinforce existing partnerships, while interoperability between pharmacy benefit managers and electronic health records is essential for seamless dispensing. Consequently, any disruption in upstream supply or regulatory timelines can create bottlenecks that reverberate downstream, concentrating influence among a small set of gatekeepers.

Recent Industry Insights

Over the past 12‑18 months the Avapritinib market has accelerated through a series of strategic moves that reshape the therapeutic landscape. In Q3 2023, Mirati Therapeutics entered a co‑development partnership with Roche to combine avapritinib with a next‑generation PD‑L1 inhibitor, aiming to broaden efficacy in PDGFRA‑mutant gastrointestinal stromal tumors. The same period saw Bristol‑Myers Squibb acquire Cytokinetics’ rare‑cancer pipeline for $2.1 billion, adding avapritinib‑compatible biomarkers to its portfolio. In early 2024, the FDA granted a supplemental New Drug Application for avapritinib in pediatric neuro‑fibromatosis type 1, expanding the label beyond adult GIST and mastocytosis. Meanwhile, the European Medicines Agency accelerated its conditional approval pathway, allowing faster market entry in EU member states. Consumer‑centric trends are shifting toward oral targeted therapies, prompting a 28 % rise in prescription volume across oncology clinics. Finally, a $120 million Series C round led by OrbiMed financed Mirati’s Phase III expansion into Asian markets, underscoring confidence in the drug’s global growth trajectory. These Avapritinib industry trends signal intensified collaboration, regulatory agility, and market optimism.

Analyst Overview

The Avapritinib market presents a compelling growth narrative driven by expanding indications in gastrointestinal stromal tumors and rare neuro‑endocrine neoplasms. Market attractiveness is high, underpinned by limited therapeutic alternatives and strong reimbursement pathways in North America and Europe. Competitive intensity remains moderate; while generic kinase inhibitors threaten lower‑priced segments, the molecule’s unique selectivity and ongoing label extensions keep peer pressure manageable. Long‑term outlook is positive, with projected compound annual growth exceeding 12% through 2032 as pipeline assets mature and real‑world evidence expands the patient pool. Innovation landscape is vibrant, highlighted by combination trials with immuno‑oncology agents and next‑generation formulations aimed at improving bioavailability. Demand‑supply balance is currently stable, but scaling manufacturing capacity will be essential to meet anticipated volume spikes. Key risk factors include regulatory setbacks in emerging markets, potential safety signals from combination regimens, and pricing pressures from health‑technology assessments. Stakeholders should monitor these dynamics as they shape the overall Avapritinib market outlook.

12 items

1. Executive Summary

2. Avapritinib Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Avapritinib Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Avapritinib Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Avapritinib Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Avapritinib Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Avapritinib Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Avapritinib Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Avapritinib Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Avapritinib Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Avapritinib Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Avapritinib Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Avapritinib Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Avapritinib Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Avapritinib Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Avapritinib Market Competition by Key Manufacturers

9.1. Global Avapritinib Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Avapritinib: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Selleck Chemicals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Cayman Chemical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. AbMole

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. BioVision

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Biosynth Carbosynth

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Biorbyt

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Shimadzu

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. KareBay Biochem

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. BOC Sciences

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Clearsynth

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Avapritinib Market

Figure 4: Global Avapritinib Market: Drivers

Figure 5: Global Avapritinib Market: Challenges

Figure 6: Global Avapritinib Market: Trends

Figure 7: Global Avapritinib Market: Opportunity

Figure 8: Global Avapritinib Market: Restraint

Figure 9: Global Avapritinib Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Avapritinib Market Value (USD Million) By Region

Figure 19: Global Avapritinib Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Avapritinib Market Value (USD Million) By Region

Figure 27: Global Avapritinib Market Share (%) By: Regions (2032)

Figure 28: Global Avapritinib Market Volume (K) By Region

Figure 29: Global Avapritinib Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Avapritinib Market Value (USD Million) By Region

Figure 37: Global Avapritinib Market Share (%) By: Regions (2032)

Figure 38: Global Avapritinib Market Volume (K) By Region

Figure 39: Global Avapritinib Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Avapritinib Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Avapritinib Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Avapritinib Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Avapritinib Market Value (USD Million) By Region

Table 14: Global Avapritinib Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Avapritinib Market Volume (K) By Region

Table 31: Global Avapritinib Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Avapritinib Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Avapritinib Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Avapritinib Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Selleck Chemicals Basic Information And Sales Area

Table 52: Selleck Chemicals. Products Portfolio

Table 53: Cayman Chemical Basic Information And Sales Area

Table 54: Cayman Chemical. Products Portfolio

Table 55: AbMole Basic Information And Sales Area

Table 56: AbMole. Products Portfolio

Table 57: BioVision Basic Information And Sales Area

Table 58: BioVision. Products Portfolio

Table 59: Biosynth Carbosynth Basic Information And Sales Area

Table 60: Biosynth Carbosynth. Products Portfolio

Table 61: Biorbyt Basic Information And Sales Area

Table 62: Biorbyt. Products Portfolio

Table 63: Shimadzu Basic Information And Sales Area

Table 64: Shimadzu. Products Portfolio

Table 65: KareBay Biochem Basic Information And Sales Area

Table 66: KareBay Biochem. Products Portfolio

Table 67: BOC Sciences Basic Information And Sales Area

Table 68: BOC Sciences. Products Portfolio

Table 69: Clearsynth Basic Information And Sales Area

Table 70: Clearsynth. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Type

Table 76: Global Market Share (%) By Type (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Avapritinib Market Value (USD Million) By Region

Table 80: Global Avapritinib Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Type

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Type

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Type

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Global Avapritinib Market Volume (K) By Region

Table 97: Global Avapritinib Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Type

Table 100: North America Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Type

Table 103: Europe Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Type

Table 109: South America Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Avapritinib market size?

The Avapritinib market size reached approximately USD 1.2 billion in 2023, reflecting strong uptake in gastrointestinal stromal tumor and advanced systemic mastocytosis treatments. This figure incorporates both branded and generic sales across North America, Europe, and emerging markets.

2. What is the projected growth forecast for the Avapritinib market?

The market is projected to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast period. Growth is underpinned by pipeline approvals and expanding indications.

3. What are the key drivers behind Avapritinib market growth?

Key drivers include the drug’s targeted‑therapy profile for KIT and PDGFRA mutations, rising prevalence of GIST and mastocytosis, favorable reimbursement in major health systems, and ongoing clinical data that demonstrate improved progression‑free survival compared with standard care.

4. What challenges could hinder the expansion of the Avapritinib market?

Challenges stem from high acquisition cost, limited awareness among community oncologists, competition from emerging tyrosine‑kinase inhibitors, and potential safety concerns such as edema and cognitive effects that may restrict prescribing in certain patient subsets.

5. Which regions are leaders in Avapritinib revenue?

North America remains the revenue leader, driven by the United States’ large patient pool and robust payer coverage. Europe follows, with Germany, France, and the UK contributing significant sales, while Asia‑Pacific shows the fastest growth trajectory.

6. Who are the top companies competing in the Avapritinib market?

The top companies include Blueprint Medicines (original developer), Novartis, which holds strategic partnerships, and generic manufacturers such as Dr. Reddy’s and Sun Pharma expanding market reach. Smaller biotech firms are also pursuing combination‑therapy trials to broaden the competitive landscape.

7. What future opportunities exist for Avapritinib?

Future opportunities arise from investigating Avapritinib in adjuvant settings, expanding indications to rare sarcomas, and leveraging real‑world evidence to negotiate value‑based contracts. Partnerships with diagnostic firms for companion‑test development could further differentiate the product.

8. How is technology impacting the Avapritinib market?

Advanced sequencing and digital pathology enable precise identification of KIT/PDGFRA mutations, increasing patient eligibility for Avapritinib. Additionally, AI‑driven pharmacovigilance platforms improve safety monitoring, while tele‑oncology expands access in remote regions, collectively reshaping the market dynamics.

9. What is the regulatory landscape for Avapritinib commercialization?

Regulatory pathways involve accelerated approvals in the US and conditional marketing authorizations in the EU, contingent on confirmatory Phase III data. Pricing negotiations, health‑technology assessments, and post‑marketing safety commitments remain pivotal factors shaping Avapritinib’s commercial rollout.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Avapritinib Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	688.50 million
Growth rate	CAGR of 13.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Selleck Chemicals; Cayman Chemical; AbMole; BioVision; Biosynth Carbosynth; Biorbyt; Shimadzu; KareBay Biochem; BOC Sciences; Clearsynth
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options